CytomX Therapeutics Inc CTMX

Healthcare Biotechnology

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.

NDAQ:CTMX - Post by User

CytomX Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by zalmonellaon Feb 02, 2022 12:47pm

119 Views

Post# 34389588

From boom to boot

Nice rise throughoutthe week, adn then last trad of the day on the 1st for 780,00 shars at whatever the market would get for it. Absolutely no news. Was someone trying to cover a short all week, and then shorted it again?

<< Previous

Bullboard Posts

Next >>

Investing in Canada's lumber market